Latest news

• Immuno-oncology, personalised medicine continues to drive pharma sector

  Despite rejecting Vitrakvi, NICE said that it was in discussions with Roche for accelerated access to its rival NTRK-inhibitor Rozlytrek (entrectinib), which is currently awaiting EU approval.

• NICE leaves the ‘the NHS door’ open despite rejecting Bayer’s Vitrakvi

  In a blow to Bayer, NICE also said in the statement that Roche’s Vitrakvi (larotrectinib) rival Rozlytrek (entrectinib) could instead become the first histology independent treatment to be made available ... Last June, NHS England chief executive Simon

• Bayer’s Vitrakvi scores first EU tumour-agnostic drug approval

  The EU approval is good news for Bayer, as it faces increasing  competition from Roche’s rival tumour-agnostic drug Rozlytrek (entrectinib). ... The list price for a month’s supply of Rozlytrek is just over $17, 000, compared to almost $33, 000 for

• Lilly’s Levi Garraway will replace Sandra Horning as Roche CMO

  The company has just picked up a new approval for targeted cancer drug Rozlytrek(entrectinib), a rival to Bayer’s Vitrakvi (larotrectinib), and for anti-CD79b antibody drug conjugate Polivy (polatuzumab

• Roche undercuts price of Bayer cancer drug after winning FDA approval

  The list price for a month’s supply of Rozlytrek is just over $17, 000, compared to almost $33, 000 for Vitrakvi. ... Writing earlier this year, analysts at Jefferies called Rozlytrek one of Roche’s “lower risk late-stage key oncology assets”.